Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer
Efficacy and Safety of PEGylated Recombinant Human Granulocyte Stimulating Factor in the Prevention of Neutropenia During Concurrent Chemoradiotherapy for Cervical Cancer
Sponsor: Chongqing University Cancer Hospital
Listed as NCT04542356, this PHASE2 trial focuses on Cervical Cancer and remains completed. Sponsored by Chongqing University Cancer Hospital, it has been updated 6 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2022 — Oct 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 1 earlier version
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chongqing University Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .